ITM Isotopes Technologies Munich has appointed Dr. Danielle Meyrick, PhD, as the company's chief medical officer. She replaces Dr. Philip Harris, who is retiring from the company.
Meyrick has over 20 years of medical research, radiotheranostic drug development, and management experience, according to ITM. She has held senior leadership roles across international biotech and radiopharmaceutical organizations including GenesisCare, AdvanCell Isotopes, and Telix Pharmaceuticals.
In her new role, Meyrick will lead ITM’s medical team in expanding and advancing the company’s radiopharmaceutical pipeline, according to the firm. She will also oversee the last stages of clinical development and commercial readiness for the phase III lead candidate, ITM-11.
